CheckMate 9ER Trial Updates

August 15, 2023

Opinion

Video

Centering discussion on the CheckMate 9ER trial, Dr. McKay shares perspective of recent follow-up data of nivolumab + cabozantinib in frontline advanced RCC.

EP: 1.Overview of Advanced RCC and Diagnosis

EP: 2.First-Line Treatment Strategies in Renal Cell Carcinoma

EP: 3.Limitations in Treatment of Metastatic Renal Cell Carcinoma

Now Viewing

EP: 4.CheckMate 9ER Trial Updates

EP: 5.CheckMate 9ER: Quality of Life Data and Treatment Implications in Advanced RCC

EP: 6.Triplet Regimens for First-Line Advanced Renal Cell Carcinoma

EP: 7.Clinical Considerations and Treatment Sequencing for Patients with Advanced RCC

EP: 8.Evolving Treatment Landscape in Advanced Renal Cell Carcinoma

Stay up to date on practice-changing data in community practice.

Subscribe Now!

Related Content

Adjuvant Pembrolizumab in Kidney Cancer: Dr Haas on KEYNOTE-564

Sabrina Serani

June 19th 2025

Article

Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Jordyn Sava;Peter Zang, MD

March 1st 2024

Podcast

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Listen

Navigating Second-Line RCC Treatment With Guidelines and Trial Data

Targeted Oncology Staff

June 17th 2025

Article

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal cell carcinoma.

Beyond the First-Line: Economides on Advancing Therapies in RCC

Jordyn Sava;Minas P. Economides, MD

February 1st 2024

Podcast

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Listen